A2RL
28.4.2024 13:58:27 CEST | Business Wire | Press release
TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/
TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire)
Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000 spectators at the circuit and captured the attention of over 600,000 online viewers in just 12 hours. Organized by ASPIRE, a subsidiary of Abu Dhabi’s Advanced Technology Research Council (ATRC), A2RL fuses extreme autonomous racing and AI to accelerate the global development of autonomous systems and technologies.
Following months of meticulous preparation spent refining driving AI algorithms in simulations, A2RL’s customized Dallara Super Formula SF23 cars tested the limits of human ingenuity and AI capability. Each team utilized an identical Super Formula race car - the fastest open-wheel race car in the world after Formula One- adapted for autonomous racing by the Technology Innovation Institute (TII), a sister company of ASPIRE.
Teams faced a complex task in coding. From understanding grip levels, managing tire temperatures, predicting opponent movements, performing successful overtakes, and operating the SF23 right at the limit of grip, the AI needed to perform all the things that racing drivers do intuitively. Additionally, with four autonomous cars racing on the track simultaneously, it marked a world-first attempt that added another layer of challenge.
In a last-lap shootout, the German outfit TUM snatched first place in a daring overtake when front-running Italian team UNIMORE slowed down and came to a stop on the track. The team was congratulated on the racetrack by H.H. Theyab bin Mohamed bin Zayed, who presented the Championship Trophy, along with H.E. Faisal Al Bannai, Secretary General, ATRC, and Strategic Research & Advanced Technology Affairs Advisor to the UAE President.
Simon Hoffmann, Team Principal, said: “This event has been nothing short of extraordinary, and the finale was our defining moment. We are absolutely thrilled with the outcome; it speaks volumes about our collective engineering prowess, coding expertise, and sheer determination. It's a testament to the incredible power of AI driving the evolution of autonomous mobility into the future!"
Spectators also enjoyed the riveting AI versus Human Race, where the Technology Innovation Institute (TII), pitted its autonomous car against renowned Formula One driver Daniil Kvyat. While Kvyat managed to hold his own and edge past his autonomous adversary by 10.38 secs, the spectacular 45-minute race highlighted just how close the autonomous race car performs against a human driver.
H.E. Al Bannai, said: “Through the Abu Dhabi Autonomous Racing League, we've sparked a race revolution. Showcasing fully autonomous racecars competing wheel-to-wheel, we've redefined the UAE's role in innovation and set a bold precedent for global mobility. This event isn't just a race; it's a transformative moment where technology, imagination, and ambition converge. A2RL serves as a beacon, inspiring the next generation through physical and virtual realities, while shaping a future where the impossible becomes achievable."
H.E. Dr. Sultan Al Jaber, Minister of Industry and Advanced Technology, and Group MD & CEO of ADNOC, as Title Sponsor, said: “Advances in artificial intelligence promise to transform every industry. The A2RL demonstrates the application of AI and as title sponsor, ADNOC is proud to help push the frontiers of science and innovation.”
Stephane Timpano, CEO of ASPIRE, said: “The launch of A2RL has reshaped the landscape of sports and technology, leaving a lasting impact for years to come. Moving forward, we're broadening our focus to include different vehicle types, while actively attracting top talent worldwide to showcase their mettle.”
On the sidelines of the main event, the A2RL STEM Challenge for high-school and undergrad students between the ages of 14 and 21 drew the participation of 18 local schools, in addition to an international entry from the Boys and Girls Club from Southeastern Michigan, to showcase their knowledge, skills, and innovation by racing 1:8 scale autonomous cars. The winner of the A2RL STEM Challenge was Heriot-Watt University.
A2RL pioneered the integration of mixed and virtual reality elements for the first time in autonomous racing. It gave each of the eight finalist teams a unique avatar persona and incorporated state-of-the-art Virtual Reality (VR) technology ahead of F1 implementation, igniting enthusiastic fan experience both online and offline. Fans at the event in Yas Marina Circuit got to enjoy insightful STEM workshops, intriguing VR challenges, Gran Turismo simulators, doodle cars, and a Raceum AI Museum, among other activities. The inaugural event concluded with a spectacular display of fireworks and drones, illuminating the iconic Yas Marina Circuit.
A2RL 2024 was successfully supported by ADNOC as Title Sponsor, and leading partners, including Du, DMT, AWS, and Mubadala, who played pivotal roles in shaping the event’s trajectory.
Details of the eight participating teams and other updates can be found at A2RL.io.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240428292385/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
